Michael Jon Brown Sells 13,000 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

Michael Jon Brown, the Executive Vice President of DexCom, Inc. (NASDAQ:DXCM), sold 13,000 shares of the company’s stock on March 12th. The shares were sold at an average price of $70.38 each, resulting in a total transaction value of $914,940.00. After this transaction, Brown retains ownership of 105,602 shares, which are valued at approximately $7,432,268.76. This sale reflects a 10.96% decrease in his holdings. The sale was officially reported to the Securities and Exchange Commission (SEC), and the details can be viewed through the SEC's website.

DexCom Stock Performance

On the following Friday, DexCom's stock saw a rise of $2.21, bringing the price to $70.69. The trading volume for the day was 4,901,859 shares, significantly higher than the average volume of 3,906,946 shares. DexCom has a market capitalization of $27.62 billion, a price-to-earnings (P/E) ratio of 49.43, and a price-to-earnings-growth (P/E/G) ratio of 2.30, indicating its valuation in the market. Over the past fifty-two weeks, the stock has fluctuated between a low of $62.34 and a high of $142.00. Additionally, the company has a current ratio of 1.47, a quick ratio of 1.28, and a debt-to-equity ratio of 0.59, highlighting its liquidity and financial stability.

Earnings Report

Recently, DexCom announced its earnings results on February 13th, reporting earnings of $0.45 per share (EPS) for the last quarter, which was below analysts' expectations of $0.50 EPS. The company noted a net profit margin of 14.29% and a return on equity of 30.14%. Analysts estimate that for the current fiscal year, DexCom will achieve an EPS of 2.03.

Wall Street Analyst Insights

Several research analysts have shared their insights regarding DexCom's stock. On March 8th, Wells Fargo maintained an “overweight” rating for DexCom shares. Earlier, in January, Baird R W upgraded the stock from a “hold” to a “strong-buy” rating. Morgan Stanley also raised their price target on the stock from $75.00 to $82.00, with an “equal weight” rating as of February 14th. Citigroup similarly increased their price target from $101.00 to $104.00 and rated it a “buy” on March 4th. Canaccord Genuity also lifted their price target to $103.00 in a research note from February 14th. Overall, DexCom holds a consensus rating of "Moderate Buy," with a collective price target of $99.82 across various analysts.

Institutional Investments in DexCom

Institutional investors have actively bought and sold shares of DexCom recently. Versant Capital Management acquired a new position valued at $25,000 in the fourth quarter. Private Trust Co. NA significantly increased its investment by 266.3%, now owning 337 shares valued at $26,000 after purchasing 245 additional shares. Other investors, including Optiver Holding B.V. and TD Private Client Wealth, have also increased their stakes. After these recent transactions, it is reported that approximately 97.75% of DexCom shares are owned by institutional entities.

About DexCom

DexCom, Inc. is a medical technology company that specializes in the design, development, and marketing of continuous glucose monitoring (CGM) systems. The company’s products are aimed at people managing diabetes and healthcare providers. Notable items in their product portfolio include the Dexcom G6 and G7 systems, Dexcom Share for remote monitoring, the Real-Time API for app integrations, and Dexcom ONE, which aims to eliminate the need for finger-prick blood tests in diabetes management.

DexCom, stock, sale